Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study.
Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study.
复制标题
使用 5 型磷酸二酯酶抑制剂的成人突发感音神经性听力损失的风险：基于人群的队列研究。
DOI：
10.1002/pds.4405
复制
发表时间：
2018
影响因子：
2.6
通讯作者：
Winterstein,AlmutG
中科院分区：
文献类型：
--
作者：
Liu,Wei;Antonelli,PatrickJ;Dahm,Philipp;Gerhard,Tobias;Delaney,JosephAC;Segal,Richard;Crystal,Stephen;Winterstein,AlmutG
PurposeThe objective of the study was to determine the risk of sudden sensorineural hearing loss (SNHL) associated with use of phosphodiesterase type 5 (PDE5) inhibitors.MethodsWe conducted a retrospective cohort study in the MarketScan Commercial Claims and Encounters Database including adult men who initiated a PDE5 inhibitor (n = 377,722) and 1,957,233 nonusers between 1998 and 2007. Periods of drug exposure were assessed on a weekly basis based on pharmacy billing records, assuming use of 1 dose per week (current use). Incident sudden SNHL was defined based on inpatient or outpatient visits with International Classification of Diseases, Ninth Revision, Clinical Modification codes 389.1x, 389.2x, or 388.2 plus ≥2 procedure codes for audiometric hearing testing within ±30 days of sudden SNHL diagnosis. We used age‐ and propensity score‐adjusted Cox proportional hazards model to evaluate the risk of sudden SNHL during periods of current or recent use compared with that of nonuse. We conducted sensitivity analyses by varying the assumed drug utilization frequency and sudden SNHL case definition.ResultsWe evaluated 1233 sudden SNHL cases, resulting in an incidence of 4.35, 5.58, and 2.38 per 10,000 person‐years for current, recent, and nonuse of PDE5 inhibitors, respectively. Compared with nonuse, the adjusted hazard ratio was 1.25 (1.01‐1.55) for current use with a risk difference of 1.97 (1.12‐2.82) per 10,000 person‐years. For recent use, the adjusted hazard ratio was 1.60 (1.33‐1.94) and risk difference was 3.19 (2.24‐4.14). Estimates were consistent across the sensitivity analyses.ConclusionsUse of PDE5 inhibitors is associated with a small but significantly increased risk of sudden SNHL.
